1. Getting the Best out of Guidelines in the Rapidly Changing Landscape of RA Treatment

3. Introduction/Background

4. Guidelines for the Treatment of RA

5. ACR Guidelines for Treatment of Early RA

6. Preliminary EULAR Guidelines: 2016

7. RA Treatment Goals in the 21st Century: EULAR and ACR

8. T2T Approach to RA Therapeutics

9. Use of Corticosteroids in RA: Comparison of an Attenuated Combination Strategy (“COBRA-light”) Compared With the Original COBRA Strategy

10. Concerns Regarding Use of Corticosteroids in RA

11. Delayed Intervention May Mean Irreparable Loss of Function

12. EULAR Overarching Principles Regulating the Treatment of RA

13. Critique of Current RA Guidelines

14. Approaches for the Nonresponding Patient in RA

15. Types of Therapies for RA

16. JAK Inhibitors

17. Guidelines: Broad Range of Pharmacotherapies Available, But No Clear Selection Criteria

18. An Approach to Personalized Medicine

19. Taking Into Account Patient Preferences

20. The Importance of Physician/Patient Communication

21. Preliminary EULAR Guidelines: 2016

22. Safety Concerns With bDMARDs in RA

23. Appropriate Management of RA

24. Prevention of RA by B-Cell-Directed Therapy in the Earliest Phase of the Disease: The PRAIRI Study

25. RA Guidelines: Practice What You Preach?

26. Three Key Components in the "Lifecycle" of Treatment Guidelines

27. Summary and Conclusions

28. Abbreviations

29. Abbreviations (cont)